Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [356]
News [1749]
Articles [85]
Editorials [3]
Conferences [74]
elearning [15]

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )
27 Jan 2022

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )
27 Jan 2022

OncoAlert Colloquium Day 4: GI oncology and EONS

Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken
OncoAlert Colloquium Day 4: GI oncology and EONS ( Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken )
19 Jan 2022

OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Oct 2021

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Oct 2021

Radioembolisation with chemotherapy for colorectal liver metastases

Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA
Radioembolisation with chemotherapy for colorectal liver metastases ( Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA )
28 Sep 2021

Pancreatic and Hepatobiliary Cancers

Dr Caio Max Rocha Lima - Wake Forest Baptist Health, North Carolina, USA
Pancreatic and Hepatobiliary Cancers ( Dr Caio Max Rocha Lima - Wake Forest Baptist Health, North Carolina, USA )
28 Jul 2021

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )
13 Apr 2021

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation